CSIMarket
 
Anixa Biosciences Inc   (ANIX)
 

The company declared operating shortfall in the first quarter of 2023

company announced first quarter of 2023 operating deficit of $-2.556 millions


Published Mar 27 2023
CSIMarket Team / CSIMarket.com


Dryvax_pd The shareholders haven't anticipated any adjustments at the business during the the earnings cycle of fiscal November to January 31 2023 at the company. Yet, stockholders monitor ANIXs' operating shortfall which has been at $-2.556 millions, during the matching time.

Such numbers represent an improvement from those the first quarter of 2022, where the operating shortfall has been at $-3.88 millions, this is just one of major signs for the situation at the company. Because evolving corporations like the ANIX, still build up the respective revenue streams, it's crucial for the businesses to run efficiently, to attain the next level.


Because the company is still growing the revenue streams, somehow ANIX has managed to curb the deficit in the financial first quarter of 2023 to $-2.354 millions, from the $-3.879 millions, in the first quarter of 2022.


Anixa Biosciences Inc is expected to report next financial recent numbers on June 09, 2023.



Anixa Biosciences Inc's Operating Margin

Anixa Biosciences Inc's Capital Expenditures Growth



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com